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Influence of Phosphatidylethanolamine Concentration
and Composition on the Detection of
Antiphosphatidylethanolamine Antibodies by ELISA
Ke Ke,1 Zachariah I. Strango,2 Paul E. Harper,2 and Ming Zhao1 ∗
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Department of Medicine, Feinberg Cardiovascular Research Institute, Northwestern University,
Chicago, Illinois
2
Department of Physics & Astronomy, Calvin College, Grand Rapids, Michigan
Background: Accumulating evidence supports a positive correlation between the
presence of antiphosphatidylethanolamine
(aPE) autoantibodies and clinical symptoms of antiphospholipid syndrome (APS).
However, there is a lack of standardized
ELISA-based method for detecting aPE.
The current study was conducted to investigate the dependence of aPE ELISA
on lipid concentration and composition of
PE antigens. Methods: A range of ELISA
conditions were examined by varying the
concentrations of egg PE and by substituting egg PE with combinations of synthetic DOPE and DSPE. The physical properties of the synthetic PE species were
also characterized. Results: Our data in-

dicated that there are different optimal PE
concentrations for conducting ELISA assays for cofactor-dependent and cofactorindependent aPEs. In addition, using a
two-component synthetic lipid system, we
demonstrated aPE ELISA readouts can be
modulated to approach the performance
level of egg PE, which is currently the most
commonly used PE antigen. Conclusion:
These data raised the possibility of ultimately replacing natural PE antigens with
a blend of defined synthetic lipid species,
thus overcoming a known variable factor in
aPE detection. The outcome of this study
will help pave the way to developing a standardized aPE test. J. Clin. Lab. Anal. 30:
C 2016 Wiley Periodicals, Inc.
689 –696, 2016. 
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INTRODUCTION
The clinical diagnosis of antiphospholipid syndrome
(APS) requires the detection of persistent presence of circulating antiphospholipid antibodies (aPL) in association
with clinical symptoms such as vascular thrombosis and
recurrent pregnancy losses. The laboratory criteria of aPL
for the classification of APS include lupus anticoagulant,
anticardiolipin antibodies, and anti-β2-glycoprotein I antibodies (1–3). However, in some instances, patients with
clinical manifestations highly suggestive of APS lack any
of the previously mentioned aPL (4–8). These are referred
to as seronegative APS.
Accumulating evidence has shown that antibodies directed against phosphatidylethanolamine (PE) lipids, a
class of lipids with zwitterionic PE head group, are
strongly associated with similar or identical clinical symptoms of APS, in the absence of the laboratory criteria of
this syndrome (9–11). The investigation of anti-PE anti-
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bodies (aPEs) would impact the clinic diagnosis of unexplained thrombosis and recurrent pregnancy losses, therefore benefiting the treatment outcome of APS.
ELISA is the most common assay for the detection of
aPE in patient serum samples. However, there is currently
no standardized aPE ELISA protocol, and a number of
variations in aPE ELISA conditions have been reported
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in aPE literature. It has been shown that different sources
of PE impact ELISA signals to some extent. Other variations in ELISA assay are attributed to the material of microplates, buffer systems, and cofactor supplement used
for aPE detection (12–15). Altogether, prior studies reveal
an inconsistent comparison among aPE detection data
from different laboratories and raised a need for standardization of the assay.
In the current study, in an effort to investigate an optimal assay condition for aPE detection, we examined the
influence of antigen concentration and composition on
the outcome of aPE ELISA. These results will contribute
to a better understanding, and ultimately lead to the standardization of aPE ELISA assay conditions.

MATERIALS AND METHODS
Patients
The study was approved by the Northwestern University Institutional Review Board and was conducted
under the NIH guidelines. All patient serum samples
were referred for antiphospholipid antibody (Ab) testing and the selected samples were positive for aPE antibodies when tested by the HLA-Vascular Biology Laboratory at Franciscan St. Francis Health, Indianapolis. Twenty-four aPE-positive serum samples were included for this study. Ten were cofactor-dependent IgG,
three were cofactor-independent IgG, three were cofactordependent IgM, and eight were cofactor-independent
IgM. Blood was collected into serum separator vacutainer
tubes without anticoagulant and serum was separated
by centrifugation. Pooled normal serum control was included in each assay. Aliquots were stored frozen at –70ºC
until use.

from light. Each well was blocked for 2 h at RT with 10%
BSA in PBS followed by 50 μl of patient serum diluted
1/100 in PBS containing 1% BSA for 1 h at RT. aPEs were
assessed by using alkaline phosphatase conjugated polyclonal Ab against either human IgG or IgM. The plates
were washed three times with PBS after blocking, serum
and conjugate incubations. After color development with
paranitrophenyl phosphate as substrate, optical density
(OD) at 405 nm was measured. OD values of pooled normal serum control were subtracted from those of patient
serum samples measured with the same PE concentration. For each patient sample measured with various PE
concentrations, OD variations were expressed as the percentage of the highest OD value obtained among various
PE concentrations.
Cofactor-Dependent Patients
aPE ELISA assays were performed as described previously for plasma protein dependent patients, with the following modifications (14). After being coated with phospholipids, ELISA wells were blocked for 2 h at RT with
10% BSA in TBS followed by 50 μl of patient serum
diluted 1/100 in TBS with 1% BSA in the presence or
absence of 10% adult bovine plasma (ABP) for 1 h at RT.
aPEs were then assessed by using alkaline phosphatase
conjugated polyclonal Ab against human IgG.
DSC Measurements
DSC (differential scanning calorimetry) measurements
were made using a TA Instruments (New Castle, DE) Q20
differential scanning calorimeter. Mixed samples were

Phospholipids
All phospholipids were purchased from Avanti Polar
Lipids and used without further purification. The concentrations of phospholipid stocks were determined by
the Bartlett method (16).
ELISA
Cofactor-Independent Patients
aPE ELISA assays were performed as described, with
the following modifications (14). Briefly, microtiter plates
(PolySorp, Thermo Fisher, Pittsburgh, PA) were coated
with 50 μl of a solution containing various concentrations
of egg yolk PE or equal molar amounts of dioleoyl PE
(DOPE) in ethanol:chloroform (4:1) and dried by evaporation at room temperature (RT) in an extractor shielded
J. Clin. Lab. Anal.

Fig. 1. An example of normalized cofactor-independent aPE reactivities with increasing egg yolk PE (◦) or DOPE (•) concentrations. Background aPE reactivities for pooled normal serum were subtracted from
aPE reactivities for patient serum obtained at the same PE concentration. Then, aPE reactivities for patient serum at certain concentration
were normalized to aPE reactivities obtained at the optimum PE concentration. Data are mean ± SD, n = 3.
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Fig. 2. Box plot of normalized aPE reactivities with increasing egg yolk PE (A and C) or DOPE (B and D) concentrations. Top panels (A and B)
are patients with cofactor-dependent aPE, n = 13; bottom panels (C and D) are serum samples with independent aPE, n = 11. The box gives the
25th to 75th percentiles, with the median given by the line inside the box. Whiskers above and below the box indicate the 10th and 90th percentiles,
with outliers given by dots.

made by adding appropriate amounts of DOPE and distearoyl PE (DSPE) to a sample pan for a total lipid sample of a few milligrams. High-purity cyclohexane (Sigma
Aldrich, St. Louis, MO.) was added to dissolve and mix
the lipids; the cyclohexane was evaporated off and the
weight of the sample pan checked to insure all of the
solvent had evaporated. An amount of deionized water
matching or exceeding the lipid weight was added and
the sample was sealed using a Tzero hermetic lid and
Tzero press (TA Instruments). Samples were heated and
cooled at 0.2°C/s to ensure mixing and were then heated
and cooled at least twice at rates of 0.1, 0.05, 0.02, and
0.01°C/s. The phase transition temperature seen on heating was plotted versus the temperature seen on cooling
and fit to a straight line; the equilibrium transition temperature was found by determining the intersection of this
line and the line where the heating and cooling temperatures are equal.

RESULTS AND DISCUSSION
Influence of PE Concentration on aPE Detection
In order to determine the optimal concentration of antigen in aPE ELISA, wells were coated with a series of concentrations of egg yolk PE ranging from 1 to 400 μg/ml.
aPEs or normal control serum were assessed with alkaline
phosphatase conjugated polyclonal Ab to either IgG or
IgM. For each sample, the OD values of pooled normal
serum indicating the level of nonspecific binding were systematically subtracted from the OD values obtained with
patient serum at the same PE concentration. OD values
of each patient serum sample at different PE concentrations, ranging from 1 to 400 μg/ml, were normalized to
the highest OD value obtained for the patient. Figure 1
shows an example of normalized independent aPE reactivities as a function of egg yolk PE or synthetic DOPE
concentrations from a representative patient serum. With
J. Clin. Lab. Anal.
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Fig. 3. Normalized aPE reactivities with increasing PE concentrations
in the absence (◦) or presence (•) of ABP. Data are mean ± SD, n = 3.

antigen concentrations increasing from 1 to 400 μg/ml,
aPE reactivities increased and peaked at around 5 μg/ml
and then gradually decreased.
Among the 24 serum samples tested, 13 of them were
cofactor dependent, which required ABP to achieve optimum ELISA readouts. Besides such a difference in

ELISA procedure, these two types of serum samples
also showed differences in the plot of normalized aPE
reactivities versus PE concentrations (Fig. 2). Comparatively, cofactor-dependent samples required a greater
antigen concentration to achieve appreciable signal levels. For instance, 1 μg/ml PE hardly resulted in a detectable reactivity with cofactor-dependent aPE samples
(Fig. 2A and B), whereas independent samples already
showed a decent level of reactivity (Fig. 2C and D). It
became apparent that there is a difference between dependent and independent samples in the antigen concentration required to achieve maximal aPE reactivity:
the concentration of PE for plasma protein dependent
serum was within a board range from about 20 to 100
μg/ml (Fig. 2A and B), whereas the concentration of
PE for independent samples to reach maximum readouts
fell in a much narrower range around 5 μg/ml (Fig. 2C
and D). For cofactor-dependent samples, adding ABP in
ELISA not only enhanced the reactivity with PE but also
right shifted the curve of normalized aPE reactivities versus PE concentrations. Figure 3 showed a representative
curve of normalized aPE reactivities with increasing PE

Fig. 4. Box plot of normalized cofactor-independent aPE reactivities with increasing egg yolk PE (A and C) or DOPE (B and D) concentrations
for IgG (A and B, n = 3) and IgM (C and D, n = 8) isotypes. The box gives the 25th to 75th percentiles, with the median given by the line inside the
box. Whiskers above and below the box indicate the 10th and 90th percentiles, with outliers marked by solid dots.
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Fig. 5. Box plot of cofactor-dependent aPE reactivities with increasing concentrations of either egg yolk PE (A and C) or DOPE (B and D) for
IgG (A and B, n = 10) and IgM (C and D, n = 3). The box gives the 25th to 75th percentiles, with the median given by the line inside the box.
Whiskers above and below the box indicate the 10th and 90th percentiles, with outliers marked by solid dots.

concentrations for ELISA in the absence or presence of
ABP.
It is notable that different Ab isotypes did not result in
significant variations in the optimal range of PE concentrations for ELISA readout. More specifically, cofactorindependent aPE serum samples consisted of three IgG
and eight IgM isotypes. When ELISA reactivity as a
function of PE concentration is plotted based on individual isotypes (i.e., IgG vs. IgM), the optimal range
was consistent between the two isotypes (Fig. 4A vs.
C and B vs. D). For cofactor-dependent samples, there
were ten IgG and three IgM isotypes. Again, the optimal PE concentration for ELISA readout was comparable between the two isotypes (Fig. 5A vs. C and
B vs. D).
Influence of PE Composition on aPE Detection
Currently, aPE ELISA assays involve variable reagents
and protocols among laboratories, which contribute to inconsistent comparisons of aPE ELISA data. The source of
antigen PE has been considered as one of the parameters

that affect the sensitivity and reproducibility of ELISA
(14). Egg yolk is currently the most common source of
antigen PE used in aPE ELISA. PE compositions from
nature sources, such as the egg, brain or bacteria, can be
highly variable, differing in fatty acid compositions, such
as the length of the fatty acid chains, as well as the ratios
and locations of saturated to unsaturated bonds in acyl
chains. The differences between manufacturers or even
different batches from one manufacturer could affect the
packing and conformation of lipid molecules, contributing to uncertainties in aPE detection. To this end, synthetic lipids are chemically homogenous. A goal of the
current study was to explore the possibility of identifying a blend of synthetic lipids with defined composition
to mimic the antigenic properties of natural PE. When
DOPE alone was compared with egg yolk PE in the current study, as shown in Figure 1, PE origin does not appear
to influence the dependence of aPE readouts as a function
of PE concentrations. However, the absolute OD value obtained at 5 μg/ml egg yolk PE was higher than the value at
same molar concentration of DOPE (Fig. 6). According
to existing literature on phospholipid analysis, egg yolk
J. Clin. Lab. Anal.
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Fig. 6. Normalized aPE reactivities for binary DOPE/DSPE mixtures
(•) and egg yolk PE (). aPE reactivities were measured using 5 μg/ml
egg yolk PE or equal molar amount of PE containing binary mixtures
of DOPE and DSPE. aPE reactivities with different PE compositions
were normalized to aPE reactivities with 100% DOPE. Data are mean
± SD, n = 4. * P < 0.5, ** P < 0.05, *** P < 0.005.

PE consists of different species of PE molecules, including
about 60% saturated and 40% unsaturated PE. The length
of fatty acid chain also varies, with around 20% C16 , 60%
C18 , 10% C20 , and 10% C22 (17). As shown in Figure 6, by

Fig. 8. Phase diagram for DOPE/DSPE mixtures. The transitions between the solid and two-phase region (filled symbols) and the two-phase
and liquid region (open symbols) were measured by DSC. Uncertainties are comparable to the symbol size. Solid lines indicate the phase
boundaries suggested by the data.

adding different percentages of DSPE into DOPE, aPE
reactivities can be modulated in a composition-dependent
fashion. The lipid compositions of 75% DOPE and 25%
DSPE, or 50% DOPE and 50% DSPE show an increased
reactivity compared to 100% DOPE, raising the likeli-

Fig. 7. A diagram showing distinct physical phases of lipids. In the lamellar phases, the lipid sheets stack to form multilamellar vesicles. In the
inverted hexagonal phase, multiple cylinders of lipids stack, and are surrounded by a bounding monolayer in order to keep the hydrophobic tails
away from aqueous environment.

J. Clin. Lab. Anal.
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hood that the antigen PE from natural sources, such as
the egg, can eventually be substituted with synthetic lipid
compositions that can ensure consistency and optimized
ELISA readouts.
Phase analysis was conducted to characterize the physical properties of the two-component lipid mixture. PE
lipids, or lipids with PE head groups, typically form the
phases illustrated and described in Figure 7. At lower temperatures, a frozen or gel lamellar (Lβ ) phase is formed. At
intermediate temperatures, the fluid lamellar (Lα ) phase
is present and at elevated temperatures the lipids form the
nonlamellar HII phase. The temperatures at which these
phases occur depend decisively on the tail structure (18).
DOPE has two identical monounsaturated tails and an
Lα - HII phase transition of 3°C (19). DSPE has two identical saturated tails; DSPE has an Lα - HII phase transition
of 100°C. Egg PE generally exhibits a Lβ - Lα transition
around 5°C and a Lα - HII transition at around 30°C (20).
A single lipid system at equilibrium generally forms only
one phase at a given temperature; systems composed of
two lipids at equilibrium can form two phases at a given
temperature. The phase diagram for DOPE/DSPE mixtures at 6.25, 12.5, 25, 50, 17, and 100% DOPE balanced
with DSPE is shown in Figure 8. At higher temperatures,
around or above the melting temperature of DSPE, the
lipid mixtures form a fluid phase; at lower temperatures,
around or below the melting temperature of DOPE, the
lipid mixtures form solid phases. In between these extremes, they phase separate into a solid, DSPE-rich phase
and a liquid, DOPE-rich phase.
These properties can guide our interpretation of the
normalized reactivities of DOPE/DSPE mixtures shown
in Figure 7. A general trend is that DSPE-rich mixtures
have lower reactivities than DOPE-rich mixtures. We can
hypothesize that the fluid nature of DOPE at the temperature at which the ELISA assays were conducted made
DOPE more reactive with the aPE. However, as pure
DOPE goes to the inverted hexagonal phase, the apparent drop in reactivity may be due to the fact that most of
the DOPE forms cylinders that might be inaccessible to
the aPE, leaving only the bounding monolayer available
to interact with the aPE (Fig. 8). As such, the current
data demonstrated that aPE ELISA reactivities can be
modulated by adjusting the physical forms of lipid mixture, and that the ELISA data were consistent with phase
measurements using DSC. These data are indicative that,
with future studies, the blend of synthetic lipids may ultimately replace PE antigens from natural sources, thus
eliminating a major factor of uncertainty in aPE ELISA.
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